mycobacterial

This is particularly relevant in chronic infections such as mycobacterial diseases (that include tuberculosis) and

PhysOrg.com - latest science and technology news stories 2010

"mycobacterial" gene pool (e.g. PE and PPE proteins, MCE and YrbE proteins, lipoprotein LpqH precursors).

Elites TV 2009

It's worth noting that Mycobacterium spp do have SOS systems (most bacteria do) but that they aren't required for many of the known mycobacterial mutations.

Browsing the Latest Issue of Scientific American 2006

I'm not sure what you are referring to by 'known mycobacterial mutations', but the main polymerase responsible for induced mutagenesis in M. tuberculosis including antibiotic resistance following infection

Browsing the Latest Issue of Scientific American 2006

It's worth noting that Mycobacterium spp do have SOS systems (most bacteria do) but that they aren't required for many of the known mycobacterial mutations. but we must believe that RMs must be able and creative enough to create a built-in machinery that can invent new enzymes required for chemical resistance!

Browsing the Latest Issue of Scientific American 2006

The clinical diagnosis can also be made difficult by associated diseases such as cryptosporidium, disseminated cryptococcosis, cytomegalovirus infection or mycobacterial infection.

Chapter 6 2000

Buruli ulcer is estimated to be the third most common mycobacterial infection in the world after tuberculosis and leprosy.

Chapter 2 1998

Item: No infertiles; no disabled; no one over 30, except on the crews; no one under 17; no one with a family history of cancer, insanity, epilepsy, mycobacterial infection, opposition to the Matriarchy, or about two hundred other genetic or possibly genetic defects; no one with a personal history of (nearly five thousand) medical conditions; no one convicted of a major crime.

And all the Stars a Stage Blish, James 1960

"We continue to believe Arikace™ has the potential to be an important treatment option for CF patients and those suffering from non-tuberculous mycobacterial NTM lung disease based on the efficacy and safety data generated from our phase 2 clinical trial program," said

unknown title 2011

Industry Canada's Industrial Technologies Office formerly Technology Partnerships Canada has contributed to the development of Bioniche's mycobacterial cell wall technologies by means of a C$9.6 million loan to be repaid by Bioniche from sales.

unknown title 2011